Advertisement

Molecular structural basis of ligand selectivity for 5-HT2 versus 5-HT1C cortical receptors

  • Pamela A. Pierce
  • Joanne Y. Kim
  • Stephen J. Peroutka
Article

Summary

A molecular structural criterion of ligand selectivity for the 5-HT2 versus 5-HT1C receptor was hypothesized on the basis of radioligand binding data. Despite the large number of compounds which have been tested at both receptors, analysis of published data led to the identification of only five agents which are greater than 10-fold selective for the 5-HT2 versus the 5-HT1C receptor. Comparison of the two-dimensional structures revealed that, although these five compounds represent three distinct structural classes, they share a common structural feature located in the region hypothesized to be involved in receptor binding: a carbonyl or carboxyl oxygen interposed spatially between an aromatic ring and nitrogen atom. This structural feature was used to predict the relative selectivity of compounds that had not previously been analyzed at both the 5-HT2 and 5-HT1C receptors.

All six drugs tested which contain the identified reactive carbonyl or carboxyl group were found to be selective for the 5-HT2 versus the 5-HT1C receptor with selectivity ratios ranging from 26 to 380. By contrast, three agents which are structurally similar but do not contain the reactive carbonyl or carboxyl group displayed equally high affinity for both receptor binding sites. Since the physiological roles of the 5-HT2 and 5-HT1C receptor are markedly different, it would be of potential clinical and scientific value to utilize this molecular structural feature to further identify chemical compounds which would selectively interact with only one of the two receptors.

Key words

5-HT2 receptor 5-HT1C receptor 5-HT ligand selectivity 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Andorn AC, Huang E, Warren AE (1984) Specific [3H]-spiroperidol binding sites in human prefrontal cortex: potential site multiplicity and overall serotonin-like selectivity. Life Sci 34:2461–2466Google Scholar
  2. Battaglia G, Shannon M, Borgundvaag B, Titeler M (1983) pH-Dependent modulation of agonist interactions with [3H]-ketanserin-labelled S2 serotonin receptors. Life Sci 33:2011–2016Google Scholar
  3. Battaglia G, Shannon M, Titeler M (1984) Guanyl nucleotide and devalent cation regulation of cortical S2 serotonin receptors. J Neurochem 43:1213–1219Google Scholar
  4. Blackburn TP, Thornber CW, Pearce RJ, Cox B (1988) In vitro studies with ICI 169369, a chemically novel 5-HT antagonist. Eur J Pharmacol 150:247–256Google Scholar
  5. Closse A (1983) [3H]Mesulergine, a selective ligand for serotonin-2 receptors. Life Sci 32:2485–2495Google Scholar
  6. Conn PJ, Sanders-Bush E (1984) Selective 5-HT-2 antagonists inhibit serotonin-stimulated phosphatidylinositol metabolism in cerebral cortex. Neuropharmacology 8:993–996Google Scholar
  7. Conn PJ, Sanders-Bush E (1987) Relative efficacies of piperazines at the phosphoinositide hydrolysis-linked serotonergic (5-HT-2 and 5-HT-1C) receptors. J Pharmacol Exp Ther 242:552–557Google Scholar
  8. Conn PJ, Sanders-Bush E, Hoffman BJ, Hartig PR (1986) A unique serotonin receptor in choroid plexus is linked to phosphoinositide hydrolysis. Proc Natl Acad Sci USA 83:4086–4088Google Scholar
  9. Creese I, Snyder SH (1978) 3H-Spiroperidol labels serotonin receptors in rat cerebral cortex and hippocampus. Eur J Pharmacol 49: 201–202Google Scholar
  10. Doyle VM, Creba JA, Ruegg UT, Hoyer D (1986) Serotonin increases the production of inositol phosphates and mobilises calcium via the 5-HT2 receptor in A7r5 smooth muscle cells. Naunyn-Schmiedeberg's Arch Pharmacol 333:98–103Google Scholar
  11. Dudley MW, Wiech NL, Miller FP, Carr AA, Cheng HC, Roebel LE, Doherty NS, Yamamura HI, Ursillo RC, Palfreyman MG (1988) Pharmacological effects of MDL 11939: a selective, centrally acting antagonist of 5-HT2 receptors. Drug Dev Res 13:29–43Google Scholar
  12. Elliott JM, Kent A (1989) Comparison of [125I]iodolysergic acid diethylamide binding in human frontal cortex and platelet tissue. J Neurochem 53:191–196Google Scholar
  13. Engel G, Göthert M, Hoyer D, Schlicker E, Hillenbrand K (1986) Identity of inhibitory presynaptic 5-hydroxytryptamine (5-HT) autoreceptors in the rat brain cortex with 5-HT1B binding sites. Naunyn-Schmiedeberg's Arch Pharmacol 332:1–7Google Scholar
  14. Fozard JR, Mir AK, Middlemiss DN (1987) Cardiovascular response to 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) in the rat: site of action and pharmacological analysis. J Cardiovasc Pharmacol 9:328–347Google Scholar
  15. Fuller RW, Mason NR, Snoddy HD, Perry KW (1986) 1-(1-Naphthyl)-piperazine, a central serotonin agonist. Res Commun Chem Pathol Pharmacol 51:37–45Google Scholar
  16. Glaser T, Traber J (1985) Binding of the putative anxiolytic TVX Q7821 to hippocampal 5-hydroxytryptamine (5-HT) recognition sites. Naunyn-Schmiedeberg's Arch Pharmacol 329:211–215Google Scholar
  17. Glennon RA, Slusher RM, Lyon RA, Titeler M, McKenney JD (1986) 5-HT1 and 5-HT2 binding characteristics of some quipazine analogues. J Med Chem 29:2375–2380Google Scholar
  18. Hamik A, Peroutka SJ (1989) 1-(m-Chlorophenyl)piperazine (mCPP) interactions with neurotransmitter receptors in the human brain. Biol Psych 25:569–575Google Scholar
  19. Hartig PR, Kadan MJ, Evans MJ, Krohn AM (1983) 125I-LSD: a high sensitivity ligand for serotonin receptors. Eur J Pharmacol 89:321–322Google Scholar
  20. Hartig PR, Evans MJ, Krohn AM, Leder SA, Sze PC, Stoffers DA (1985) [125I]LSD binding to serotonin and dopamine receptors in bovine caudate membranes. Neurochem Int 7:699–707Google Scholar
  21. Hibert MF, Gittos MW, Middlemiss DN, Mir AK, Fozard JR (1988) Graphics computer-aided receptor mapping as a predictive tool for drug design: Development of potent, selective and stereospecific ligands for the 5-HT1A receptor. J Med Chem 31:1087–1093Google Scholar
  22. Hoffman BJ, Scheffel U, Lever JR, Karpa MD, Hartig PR (1987) N1-Methyl-2-125I-lysergic acid diethylamide, a preferred ligand for in vitro and in vivo characterization of serotonin receptors. J Neurochem 48:115–124Google Scholar
  23. Hoyer D (1988a) Molecular pharmacology and biology of 5-HT1C receptors. Trends Pharmacol Sci 9:89–94Google Scholar
  24. Hoyer D (1988b) Functional correlates of serotonin 5-HT1 recognition sites. J Recept Res 8:59–81Google Scholar
  25. Hoyer D (1989) 5-Hydroxytryptamine receptors and effector coupling mechanisms in peripheral tissues. In: Fozard J (ed) Peripheral action of 5-HT. Oxford University Press, Oxford, pp 72–99Google Scholar
  26. Hoyer D, Karpf A (1988) [125I]SCH 23982, a ‘selective’ D-1 receptor antagonist, labels with high affinity 5-HT1C sites in pig choroid plexus. Eur J Pharmacol 150:181–184Google Scholar
  27. Hoyer D, Engel G, Kalkman HO (1985) Molecular pharmacology of 5-HT1 and 5-HT2 recognition sites in rat and pig brain membranes: radioligand binding studies with [3H] 5-HT, [3H] 8-OH-DPAT, (−) [125I]iodocyanopindolol, [3H] mesulergine and [3H]ketanserin. Eur J Pharmacol 118:13–23Google Scholar
  28. Hoyer D, Pazos A, Probst A, Palacios JM (1986) Serotonin receptors in the human brain. II. Characterization and autoradiographic localization of 5-HT1C and 5-HT2 recognition sites. Brain Res 376:97–107Google Scholar
  29. Hoyer D, Vos P, Closse A, Palacios JM, Engel G, Davies H (1987) [3H]Ketanserin labels serotonin 5-HT2 and alpha1-adrenergic receptors in human brain cortex. J Cardiovasc Pharmacol 10 [Suppl 3]:S48-S50Google Scholar
  30. Hoyer D, Waeber C, Schoeffter P, Palacios JM, Dravid A (1989) 5-HT1C receptor-mediated stimulation of inositol phosphate production in pig choroid plexus. Naunyn-Schmiedeberg's Arch Pharmacol 339:252–258Google Scholar
  31. Julius D, MacDermott AB, Axel R, Jessell TM (1988) Molecular characterization of a functional cDNA encoding the serotonin 1c receptor. Science 241:558–564Google Scholar
  32. Kadan MJ, Krohn AM, Evans MJ, Waltz RL, Hartig PR (1984) Characterization of 125I-lysergic acid diethylamide binding to serotonin receptors in rat frontal cortex. J Neurochem 43:601–606Google Scholar
  33. Kendall DA, Nahorski SR (1985) 5-Hydroxytryptamine-stimulated inositol phospholipid hydrolysis in rat cerebral cortex slices: Pharmacological characterization and effects of antidepressants. J Pharmacol Exp Ther 233:473–479Google Scholar
  34. Kobilka BK, Kobilka TS, Daniel K, Regan JW, Caron MG, Lefkowitz RJ (1988) Chimeric alpha-2, beta-2 adrenergic receptors: Delineation of domains involved in effector coupling and ligand binding specificity. Science 240:1310–1316Google Scholar
  35. Leysen JE (1990) Gaps and peculiarities in 5-HT2 receptor studies. Neuropsychopharmacology 3:361–369Google Scholar
  36. Leysen JE, Niemegeers CJE, Tollenaere JP, Laduron PM (1978) Serotonergic component of neuroleptic receptors. Nature 272:168–171Google Scholar
  37. Leysen JE, Niemegeers CJE, Van Nueten JM, Laduron PM (1982) [3H] Ketanserin (R 41468), a selective 3H-ligand for serotonin2 receptor binding sites. Mol Pharmacol 21:301–314Google Scholar
  38. Leysen JE, Van Gompel P, Gommeren W, Woestenborghs R, Janssen PAJ (1986) Down regulation of serotonin-S2 receptor sites in rat brain by chronic treatment with the serotonin-S2 antagonists: ritanserin and setoperone. Psychopharmacology 88:434–444Google Scholar
  39. Leysen JE, Gommeren W, Van Gompel P (1988) The dissociation rate of unlabelled drugs from receptor sites: a poorly investigated, yet important aspect in receptor research. Studies on the serotonin-S2 receptor. J Recept Res 8:547–559Google Scholar
  40. Lindvall-Axelsson M, Mathew C, Nilsson C, Owman CH (1988) Effect of 5-hydroxytryptamine on the rate of cerebrospinal fluid production in rabbit. Neurology 99:362–368Google Scholar
  41. Lloyd E, Andrews PR (1986) A common structural model for central nervous system drugs and their receptors. J Med Chem 29:453–462Google Scholar
  42. Lyon RA, Titeler M, Frost JJ, Whitehouse PJ, Wong DF, Wander HN, Dannals RF, Links JM, Kuhar MJ (1986) 3H-3-N-Methylspiperone labels D2 dopamine receptors in basal ganglia and S2 receptors in cerebral cortex. J Neurosci 6:2941–2949Google Scholar
  43. Lyon RA, Davis KH, Titeler M (1987) 3H-DOB (4-bromo-2,5-dimethoxyphenylisopropylamine) labels a guanyl nucleotide-sensitive state of cortical 5-HT2 receptors. Mol Pharmacol 31:194–199Google Scholar
  44. Lyon RA, Titeler M, Seggel MR, Glennon RA (1988) Indolealkylamine analogs share 5-HT2 binding characteristics with phenylalkylamine hallucinogens. Eur J Pharmacol 145:291–297Google Scholar
  45. Markstein R, Hoyer D, Engel G (1986) 5-HT1A-receptors mediate stimulation of adenylate cyclase in rat hippocampus. Naunyn-Schmiedeberg's Arch Pharmacol 333:335–341Google Scholar
  46. McKenna D, Peroutka SJ (1989) Differentiation of 5-hydroxytryptamine2 receptor subtypes using 125I-R-(−)2,5-dimethoxy-4-iodo-phenylisopropylamine and 3H-ketanserin. J Neurosci 9:3482–3490Google Scholar
  47. Neale RF, Fallon SL, Boyar WC, Wasley JWF, Martin LL, Stone GA, Glaeser BS, Sinton CM, Williams M (1987) Biochemical and pharmacological characterization of CGS 12066B, a selective serotonin-1B agonist. Eur J Pharmacol 136:1–9Google Scholar
  48. Nicklaus KJ, McGonigle P, Molinoff PB (1988) [3H]SCH 23390 labels both dopamine-1 and 5-hydroxytryptamine1C receptors in the choroid plexus. J Pharmacol Exp Ther 247:343–348Google Scholar
  49. Pazos A, Hoyer D, Palacios JM (1984a) Binding of serotonergic ligands to the porcine choroid plexus: Characterization of a new type of 5-HT recognition site. Eur J Pharmacol 106:539–546Google Scholar
  50. Pazos A, Hoyer D, Palacios JM (1984b) Mesulergine, a selective serotonin-2 ligand in the rat cortex, does not label these receptors in porcine and human cortex: evidence for species differences in brain serotonin-2 receptors. Eur J Pharmacol 106:531–538Google Scholar
  51. Peroutka SJ (1985) Selective interactions of novel anxiolytics with 5-hydroxytryptamine1A receptors. Biol Psych 20:971–979Google Scholar
  52. Peroutka SJ (1988) Antimigraine drug interactions with serotonin receptors subtypes in human brain. Ann Neurol 23:500–504Google Scholar
  53. Peroutka SJ, Snyder SH (1979) Multiple serotonin receptors: differential binding of [3H]5-hydroxytryptamine, [3H]lysergic acid diethylamide and [3H]spiroperidol. Mol Pharmacol 16:687–699Google Scholar
  54. Peroutka SJ, Snyder SH (1980) Relationship of neuroleptic drug effects at brain dopamine, serotonin, alpha-adrenergic, and histamine receptors to clinical potency. Am J Psych 137:1518–1522Google Scholar
  55. Peroutka SJ, Sleight AJ, McCarthy BG, Pierce PA, Schmidt AW, Hekmatpanah CR (1989) The clinical utility of pharmacological agents that act at serotonin receptors. J Neuropsychiatry 1:253–262Google Scholar
  56. Pierce PA, Peroutka SJ (1989a) Evidence for distinct 5-HT2 binding site subtypes in cortical membarne preparations. J Neurochem 52:656–658Google Scholar
  57. Pierce PA, Peroutka SJ (1989b) Hallucinogenic drug interactions with neurotransmitter receptor binding sites in human cortex. Psychopharmacology 97:118–122Google Scholar
  58. Pritchett DB, Bach AWJ, Wozny M, Taleb O, Toso RD, Shih JC, Seeburg PH (1988) Structure and functional expression of cloned rat serotonin 5-HT2 receptor. EMBO J 7:4135–4140Google Scholar
  59. Roth BL, Nakaki T, Chuang D, Costa E (1986) 5-hydroxytryptamine2 receptors coupled to phospholipase C in rat aorta: Modulation of phosphoinositide turnover by phorbol ester. J Pharmacol Exp Ther 238:480–485Google Scholar
  60. Roth BL, McLean S, Zhu XZ, Chuang DM (1987) Characterization of two [3H]ketanserin recognition sites in rat striatum. J Neurochem 49:1833–1838Google Scholar
  61. Sadzot B, Baraban JM, Glennon RA, Lyon RA, Leonhardt S, Jan CR, Titeler M (1989) Hallucinogenic drug interactions at human brain 5-HT2 receptors: implications for treating LSD-induced hallucinogenesis. Psychopharmacology 98:495–499Google Scholar
  62. Sanders-Bush E, Breeding M (1988) Putative selective 5-HT-2 antagonists block serotonin 5-HT-1C receptors in the choroid plexus. J Pharmacol Exp Ther 247:169–173Google Scholar
  63. Schmidt AW, Peroutka SJ (1989) Three-dimensional steric molecular modeling of the 5-hydroxytryptamine3 receptor pharmacophore. Mol Pharmacol 36:505–511Google Scholar
  64. Schoeffter P, Hoyder D (1989) Interaction of arylpiperazines with 5-HT1A, 5-HT1B 5-HT1C, and 5-HT1D receptors: do discriminatory 5-HT1B receptor ligands exist? Naunyn-Schmiedeberg's Arch Pharmacol 339:675–683Google Scholar
  65. Taylor EW, Nikam SS, Lambert G, Martin AR, Nelson DL (1988) Molecular determinants for recognition of RU 24969 analogs at central 5-hydroxytryptamine recognition sites: use of a bilinear function and substituent volumes to describe steric fit. Mol Pharmacol 34:42–53Google Scholar
  66. Titeler M, Battaglia G, Shannon M (1984) Guanine nucleotides modulate cortical S2 serotonin receptors. J Recept Res 4:705–712Google Scholar
  67. Titeler M, Lyon RA, Davis KH, Glennon RA (1987) Selectivity of serotonergic drugs for multiple brain serotonin receptors. Role of [3H]-4-bromo-2, 5-dimethoxyphenylisopropylamine ([3H]DOB), a 5-HT2 agonist radioligand. Biochem Pharmacol 36:3265–3271Google Scholar
  68. Titeler M, Lyon RA, Glennon RA (1988) Radioligand binding evidence implicates the brain 5-HT2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens. Psychopharmacology 94:213–216Google Scholar
  69. Tricklebank MD, Middlemiss DN, Neill J (1986) Pharmacological analysis of the behavioural and thermoregulatory effects of the putative 5-HT1 receptor agonist, RU 24969, in the rat. Neuropharmacology 25:877–886Google Scholar
  70. Wander TJ, Nelson A, Okazaki H, Richelson E (1987) Antagonism by reuroleptics of serotonin 5-HT1A and 5-HT2 receptors of normal human brain in vitro. Eur J Pharmacol 143:279–282Google Scholar
  71. Wouters W, Van Dun J, Laduron PM (1987) Identification of the serotonin-S2 receptor ligand binding site by photoaffinity labelling with 7-azido-8-[125I]ketanserin ([125]AZIK). FEBS Lett 213:359–364Google Scholar
  72. Yagaloff KA, Guillermina L, Van Dyke T, Levine AJ, Hartig P (1986) Serotonin 5-HT1C receptors are expressed at high density on choroid plexus tumors from transgenic mice. Brain Res 385:389–394Google Scholar
  73. Yamamoto T, Kebabian JW (1989) [125I]SCH 23 982 binds to a serotonin receptor (and not to a D-1 dopamine receptor) in the rat choroid plexus. Biogenic Amines 6:241–246Google Scholar

Copyright information

© Springer-Verlag 1992

Authors and Affiliations

  • Pamela A. Pierce
    • 1
  • Joanne Y. Kim
    • 1
  • Stephen J. Peroutka
    • 1
  1. 1.Department of NeurologyStanford University School of MedicineStanfordUSA

Personalised recommendations